☆ 4.5 Article

Myocardial infarction associated with erenumab: A case report

PHARMACOTHERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database

Alexandre O. Gerard et al.

Summary: This study found a significant association between CGRP-targeting drugs and Raynaud's phenomenon, with a stronger association compared to other drugs. However, caution is needed in the use of CGRP-targeting drugs due to limitations such as missing data and reporting bias.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Article Clinical Neurology

Hypertension: A new safety risk for patients treated with erenumab

Suprat Saely et al.

Summary: This study analyzed 61 postmarketing case reports of elevated blood pressure associated with erenumab use, with most cases occurring in women within a week of initial dose. Some cases had serious outcomes, including hospitalization, but there were no reported deaths.

HEADACHE (2021)

添加到收藏夹

Article Oncology

New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database

Maurizio Sessa et al.

Summary: This study aimed to provide an overview of adverse events reported for erenumab in post-marketing through the FDA Adverse Event Reporting System and perform a disproportionality analysis with other drugs used for acute or preventative treatment of migraine as controls. The results showed that the majority of adverse events reported were non-serious, but new safety aspects emerged which require further studies for confirmation.

BIODRUGS (2021)

添加到收藏夹

Article Clinical Neurology

Vascular safety of erenumab for migraine prevention

David Kudrow et al.

NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Stewart J. Tepper et al.

CEPHALALGIA (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans

Tessa de Vries et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

CGRP inhibitors for migraine prophylaxis: a safety review

Eduardo Rivera-Mancilla et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Article Neurosciences

Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report

Stephen Aradi et al.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2019)

添加到收藏夹

Article Clinical Neurology

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

Christophe Depre et al.

HEADACHE (2018)

添加到收藏夹

Review Physiology

The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects

Zizheng Kee et al.

FRONTIERS IN PHYSIOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Physiology

CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY

F. A. Russell et al.

PHYSIOLOGICAL REVIEWS (2014)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension

I. Marquez-Rodas et al.

JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2006)

添加到收藏夹

Review Clinical Neurology

Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache

L Edvinsson

CEPHALALGIA (2004)

添加到收藏夹

Article Clinical Neurology

An immunocytochemical investigation of human trigeminal nucleus caudalis:: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres

D Smith et al.

CEPHALALGIA (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.